Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
GVHD Prevention with PTCy, Abatacept, Vedolizumab, and Ruxolitinib in Pediatric HSCT
NCT06756152Phase 3Recruiting
- Sponsor
- Dmitry Rogachev National Medical Research Center of Pediatric Hematology, Oncology and Immunology
- Start
- Jul 2024
- Primary completion
- Jul 2026
- Modality
- Antibody Conjugates, Small Molecules, Engineered Antibody Formats
- Countries
- 1
01
Overview
A Phase 3 trial of abatacept, vedolizumab, ruxolitinib in graft-versus-host disease (GVHD), sponsored by Dmitry Rogachev National Medical Research Center of Pediatric Hematology, Oncology and Immunology. Started Jul 2024; status: recruiting.
02
Drugs
03
Conditions
graft-versus-host disease (GVHD)
Beyond the preview
Go deeper on NCT06756152.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06756152.